Tissue Biomarkers for Prognosis of Prostate Cancer: A Systematic Review and Meta-analysis

• Published in: Cancer epidemiology, biomarkers & prevention Vol. 23; no. 6; pp. 1047 - 1054
• Main Authors: Zhao, Liuyang, Yu, Na, Guo, Tianfang, Hou, Yixuan, Zeng, Zongyue, Yang, Xiaorong, Hu, Ping, Tang, Xi, Wang, Jian, Liu, Manran
• Format: Journal Article
• Language: English
• Published: Philadelphia, PA American Association for Cancer Research 01.06.2014
• Subjects: Biological and medical sciences; Biomarkers, Tumor - analysis; Gynecology. Andrology. Obstetrics; Humans; Immunohistochemistry; Male; Male genital diseases; Medical sciences; Multiple tumors. Solid tumors. Tumors in childhood (general aspects); Nephrology. Urinary tract diseases; Prognosis; Prostatic Neoplasms - chemistry; Prostatic Neoplasms - pathology; Tumors; Tumors of the urinary system; Urinary tract. Prostate gland; Human; Urinary system disease; Prognosis; Prostate disease; Biological marker; Male; Systematic review; Malignant tumor; Metaanalysis; Cancerology; Cohort study; Predictive factor; Male genital diseases; Prostate cancer; Cancer
• ISSN: 1055-9965; 1538-7755
• DOI: 10.1158/1055-9965.EPI-13-0696

Although numerous investigators have made efforts to assess prognostic biomarkers of prostate cancer, no biomarker has been recommended for clinical practice. According to REMARK (Reporting recommendations for tumor marker prognostic studies) and MISFISHIE (Minimum information specification for in situ hybridization and immunohistochemistry experiments) guidelines, the published articles of immunohistochemistry-based prognostic biomarkers on prostate cancer were extracted and pooled. Ninety-three prognostic biomarkers from 92 high-quality cohort studies were included in this meta-analysis. Our analysis reveals some promising independent prognostic biomarkers, including Ki-67 [all-cause mortality (ACM) HR, 1.85; 95% confidence interval (CI), 1.06-3.25; PSM HR, 1.82; 95% CI, 1.42-2.34; DFS HR, 1.51; 95% CI, 1.31-1.75]; Bcl-2 (ACM HR, 2.14; 95% CI, 1.27-3.58; PSM HR, 1.61; 95% CI, 1.01-2.57; DFS HR, 3.86; 95% CI, 2.14-6.96); CD147 (ACM HR, 2.63; 95% CI, 1.19-5.81; DFS HR, 5.84; 95% CI, 3.41-9.99); COX-2 (PSM HR, 7.6; 95% CI, 0.7-80.1; DFS HR, 7.9; 95% CI, 2.62-23.83); ALDH1A1 (ACM HR, 1.73; 95% CI, 1.163-2.527; PSM HR, 1.05; 95% CI, 1.028-1.107), and FVIII (ACM HR, 1.76; 95% CI, 1.19-2.60; PSM HR, 1.01; 95% CI, 1.01-1.02). Our analysis identified a subset of biomarkers (Ki-67, Bcl-2, CD147, COX-2, ALDH1A1, and FVIII) that may have prognostic value for predicting the outcome of patients with prostate cancer. These reliable prognostic biomarkers will improve the clinical management of patients with prostate cancer. Cancer Epidemiol Biomarkers Prev; 23(6); 1047-54. ©2014 AACR.